The Cancer Target Discovery and Development (CTD This manuscript represents a first attempt to delineate the challenges of supporting and confirming discoveries arising from the systematic analysis of large-scale data resources in a collaborative work environment and to provide a framework that would begin a community discussion to resolve these challenges. The Network implemented a multi-Tier framework designed to substantiate the biological and biomedical relevance as well as the reproducibility of data and insights resulting from its collaborative activities. The same approach can be used by the broad scientific community to drive development of novel therapeutic and biomarker strategies for cancer.
Introduction
Large-scale molecular characterization projects are generating comprehensive data for pediatric and adult malignancies, from hundreds to thousands of patient-derived samples [1] [2] [3] , transgenic mouse models 4 , patient-derived xenografts, and cancer cell lines [5] [6] [7] . These data allow systematic evaluation of key biologically and clinically relevant hypotheses, such as the association between drug sensitivity and specific genetic alterations, or between specific biological features and patient outcome. As a result, biomedical discovery is being increasingly driven by the integrative analyses of large amounts of data followed by experimental evaluation both in vitro and in vivo. The challenge is to capitalize on these different data sources in a systematic way that makes the process of target discovery and translation more efficient, transparent and reproducible.
Such transition from a strictly hypothesis-driven to an increasingly hypothesis-generating The questions discussed in this manuscript represent the specific challenges faced by this group of researchers as they began to develop successful, multi-center collaborations leading to numerous publications and clinical translation efforts. Specifically, CTD 2 investigators quickly realized that, while each center was an expert in the methodologies related to a specific aspect of biological discovery -from Big Data analysis to large-scale chemical-biology screens to pooled functional assays -the ability to operate at the intersection of these methodologies, especially in terms of quality control and data reproducibility. For instance, the specific quality control infrastructure and mechanisms necessary to ensure reproducibility of big data analyses or in vivo functional assays are quite different. Thus, collaborations that leverage more than one data modality require potentially orthogonal communities to develop a cross-disciplinary understanding of their individual competencies.
This is a vast and complex undertaking and as such, this perspective cannot be interpreted as a fully finished and comprehensive framework to support interdisciplinary collaborations. Rather, it represents the first essential step in motivating the community to address several critical issues on a systematic and comprehensive basis. Indeed, we envision this effort as the first of a series of manuscripts representing both a dialog and a resource for the community, which may be especially useful to young investigators and trainees as they face the complexity and challenges of large-scale collaborative research efforts that are emerging as necessary to address an equally increasing complexity of biological discovery.
In this vein, this Perspective begins to delineate the challenges of supporting and confirming discoveries arising from the systematic analysis of large-scale data resources in a collaborative environment. We provide a framework to start addressing the pivotal question: "What level of experimental evidence is necessary to complement insights derived from Big Data analysis in order to reach its potential to impact human health positively?" While our focus in this
Perspective is based entirely on a system that we have adopted within the collaborative CTD 2 Network to disseminate the hypotheses and insights resulting from this Network's research, the approach and methodology is generalizable, and is thus not limited to CTD 2 Network activities.
Furthermore, we hope that the research community will use this initially sparse framework to provide increasingly in depth insight and mechanisms to address quality control and reproducibility at the boundary of the multiple and highly complementary sub-disciplines of biological investigation.
The Network implemented a system to ensure that data and insights resulting from its activities would be reproducible 12 , and would thus be used by the CTD 2 or the scientific community to drive the development of novel therapeutic and biomarker strategies for cancer. We also hope to provide the scientific community a framework for the effective reporting of data generated by these and other methods in future applications of the knowledge derived from Big Data for biological insight. This Perspective should be seen as the first step in elucidating the critical challenges and deriving a framework that will begin a community wide discussion of the challenges that will lead to a more detailed description of the metrics needed for specific research technologies such as proteomics and drug screening analysis that have not already been systematically evaluated in the literature and through consensus white papers.
Data Sharing and Clarity
To enable clear description of novel therapeutic targets and pathways identified by the CTD Tier, we enumerate information related to three entities that are critical to the development of cancer therapeutics. These include: 1) molecular targets, 2) small-molecule or biological modulators of the targets, and 3) associated predictive or prognostic biomarkers for patient selection.
Evidence Tier Definitions
Tier 1: Preliminary positive observations. These data represent the initial results of high-throughput experiments, typically using a single experimental or computational platform; examples are given for illustration purposes only. Computational analyses: Any computational approaches and strategies including the analysis of, for example, alternatively spliced transcripts and cell surface markers and other factors that might stimulate the immune system can identify candidate cancer targets or pathways. The primary data can be from the public domain or project-specific high-throughput assays that are released into the public domain and are clearly referenced.
Small-molecule assays:
NOTE: In Tier 1, the data can support many concepts and not just targets, biomarkers, or smallmolecule perturbagens.
Tier 2: Confirmation of primary results in vitro.
These results meet the Tier 1 requirements AND have been confirmed by at least one of the following:
• More detailed version of the original assay, such as concentration-response versus single-point, high-replicate (e.g., N>4) versus low-replicate (e.g., singleton), target silencing in additional patient-relevant cell lines or models, or results from high-content microscopy experiments, etc.
• Orthogonal secondary assay or counter-screen 
Small-molecule assays:
The data include a detailed characterization of each candidate using the primary or suitable orthogonal assays. These data define the desired biological profile and may include testing in additional patient-relevant cell models. Some measure of potency and selectivity is established (e.g., selective toxicity for cancer cells over an appropriate normal cell model).
Genetic perturbation assays:
A more detailed characterization of gene candidates is required to meet the standard criteria of demonstrating that at least two independently designed genetic perturbation reagents produce the same effect. These experiments could use RNAi, CRISPR, TALENs, or ORF reagents. In addition, the possibility of an effect being due to miRNA seed sequences should be addressed. Validation of a reagent can occur through direct measurements (mRNA depletion, protein levels), computational approaches (measurements of reagents made in multiple cell lines or assays), or a combination thereof.
Biomarkers:
The specifics of a more detailed characterization of biomarkers depend on the utility of the biomarker being developed. For biomarkers aimed at identifying the patient population likely to benefit from a given therapeutic strategy, confirmation in an independent, appropriately statistically powered population for which relevant molecular profile data can be accessed is required. Biomarkers that quantify efficacy for pre-clinical or clinical measurements require validation in independent model systems. Biomarkers providing a pharmacodynamics profile for drug activity in a patient require confirmation in a distinct, appropriately statistically 
Small-molecule assays:
The data presented include orthogonal assays that further support the profile of selected compounds as being consistent with the therapeutic hypothesis. The difference from Tier 2 is two-fold: 1) at Tier 3 the experiments are carried out in vivo, and 2)
proof of mode-of-action is necessary (e.g., mitotic arrest using an image-based assay or identify the gene or molecular alteration that leads to the cancer dependency of the small-molecule activity). Biomarkers: Biomarkers as listed in Tier 3 require additional development and implementation of an analytical test system with well-established performance characteristics and cut-offs. Any associated algorithms are "locked" in terms of coefficients and other parameters. The analytic test system is used to evaluate the performance of the type-specific potential biomarkers on an independent validation patient-sample cohort. Additionally, a credible scientific framework that explains the physiologic or clinical significance of the test results is required.
Genetic perturbation assays:

Molecular interaction:
Mutational analysis of cancer-specific variants could provide supporting data for molecular interactions. Aberrant or neomorph-related interactions should be identified as distinct from those occurring in a cell's physiologic regime. Biomarkers that reflect the status of the molecular interaction target should be provided for translational studies.
Examples of transition through the Evidence Tiers to clinical trials (Figure 2)
To provide examples of how this framework facilitates the discussion and comparison of different types of targets, we describe three targets that were identified by CTD 2 members and for which further validation experiments provided substantiated hypotheses, now in testing in clinical trials.
Vignette 1: WEE1 inhibitor MK1775 (AZD1775) in head and neck squamous cell carcinoma (HNSCC)
The cell cycle checkpoint kinase WEE1 is an illustrative example of advancing a target through Such an approach highlighted how independent evidence from large scale computational and experimental assays can provide complementary clues that lead to identification of biological mechanisms with high potential for successful experimental validation, both in vitro and in vivo.
Specifically, unless they are performed in a very large number of phenotypically relevant cellular contexts, pooled RNAi screens are often not sufficiently selective to pinpoint generalizable tumor dependency mechanisms. One concern, for instance, is that these screens may highlight idiosyncratic dependencies induced by the non-physiologic nature of the cell line context used in these assays. In contrast, network-based analysis of big data from human samples to identify master regulators of tumor cell state have shown remarkable ability to pinpoint functional drivers, with validation rates in the 70% to 80% range. Yet, the latter must still be experimentally validated to separate truly biological dependencies from potential computational artifacts 4, 14, 15 .
The use of combined pooled RNAi screens with computational, network-based approaches addresses both issues providing clear complementarity and thus allowing efficient and 
Future Outlook
We introduce a multi-Tier framework designed to provide an approach to substantiate the biological and biomedical relevance, as well as the reproducibility, of novel biomedical insights arising from analysis of Big Data. Such an approach allows the systematic identification of relevant insights derived from large-scale data analyses, through a series of increasingly strict filters, rather than through a single monolithic filter, whose failure may compromise the entire validation process. The approach is not meant to be prescriptive but rather to represent the minimal data elements ensuring biological and clinical relevance. Indeed, we expect that there will be insufficient evidence to credential many targets or small molecules initially classified as Tier 1-3 as substantiated hypotheses. Nevertheless, this framework permits one to classify potential targets, biomarkers or small molecules based on the available information.
We define Evidence Tiers to clarify the levels of validation for pharmacologically accessible therapeutic targets, associated biomarkers, and biochemical modulators. In each Tier, we enumerate information related to three entities: 1) molecular targets, 2) associated predictive or prognostic biomarkers for patient selection, and 3) small-molecule or biological modulators of the targets, that are critical to the development of cancer therapeutics. Effective representation of specific hypotheses will often involve multi-modal evidence from different Tiers (e.g., a target with associated biomarkers for stratification and pharmacodynamics and a set of small-molecule modulators). We expect that systematic availability of these evidence Tiers, with additional substantiation by other CTD 2 investigators and extra-Network investigators, will motivate the use of Network-generated insight and knowledge for clinical investigation.
Experiments supporting the substantiation of any hypothesis are essential before any target is prioritized for development, either by Network Centers, other investigators or by biotechnology or pharmaceutical companies. The Evidence Tiers defined in this document help delineate and communicate the complex process of data analysis, starting from large genomic or functional data sets, and ending with the generation of pre-clinical leads for characterizing targets, small molecules, and biomarkers. We expect that new information generated by the CTD 2 Network and others will inform an improved definition of the concepts we present here. We hope that the principles of Tiers of evidence as applied in the CTD 2 Dashboard will be useful in other contexts, and thereby provide confidence in the quality, clarity and reproducibility of research performed in the public sector. 
